Capital Access Group

Capital Access Group advises companies on effective engagement with investors. Our experienced team offers market-leading access with hard-to-reach investors, including smaller institutions, pension funds and private client fund managers. These under-serviced investors are located not only in London but across the regions of the UK and Europe. We have an unrivalled knowledge of this extensive audience, to whom our published research is distributed, as well as to larger institutions. We offer this service as part of an integrated investor communications strategy to promote a company’s investment story.

Our clients, ranging from AIM to FTSE 100 companies, benefit from our professional, long-term relationships with investors. Not only do we identify and target investors, we contact them directly and relay their views back to clients with analysis, interpretation and advice. This ensures that our clients are in control of their investor engagement. The objective is to improve the reach and engagement with investors, which in turn strengthens the share price.

Colin Smith
  • Colin Smith

Polarean Imaging | Xenon MRI pharma research collaboration

Polarean has announced that its Xenon MRI lung imaging has been selected by a leading global pharma company to be included in a clinical trial due to start in 4Q25. This collaboration opens up a new vertical for Polarean but more importantly provides third party validation of the unmatched lung imaging that Polarean's Xenon MRI system provides. Polarean recently announced a better than expected update for FY24 which, in our view, confirms that the company is on the cusp of hyperbolic growth with...

Colin Smith
  • Colin Smith

Galliford Try | 1HFY25 results – Increased confidence in FY25

Further to its positive trading update, Galliford Try has delivered another excellent set of results for the half to December underlined by a 37.5% hike in the interim dividend to 5.5p. The company announced adjusted PBT for 1HFY25 of £20.5m, up 22.0% YoY. Despite the increase in consensus forecasts following the trading statement, management now expect revenue and adjusted PBT to be above the top end of the range of market forecasts which currently stand at £1,835m and £36.0m, respectively. Rev...

Colin Smith
  • Colin Smith

Seplat Energy | FY24 results - Confident 10% dividend increase

Seplat reported a near doubling in EPS for FY24 to US$0.26 (FY23 US$0.14) which included 19 days of contribution from the newly acquired MPNU assets, now renamed as Seplat Energy Producing Nigeria Unlimited (SEPNU). Excluding SEPNU and net positive unusual items, operating profit came in around 5% ahead of our forecast, we calculate. Adjusted EBITDA increased 20.3% YoY to US$539.0m on a reported basis and down 1.8% for the onshore assets. Net debt ended the year at US$898m, ahead of the US$1.1bn...

Colin Smith
  • Colin Smith

Polarean Imaging | FY24 update - Even better than expected

Polarean has published a trading update for the year to December which is even better than expected. Revenue for FY24 is anticipated to be US$3.0m-US$3.1m, above guidance of US$2.5m-US$3.0m, and more than treble revenue for FY23; our forecast was US$2.8m. Moreover, net cash at YEFY24 of US$12.1m was well above our forecast of US$10.8m and the company reiterated that it has a cash runway through 1Q26. A YoY jump in sales of over 50% in consumables demonstrates an increase in the number of Xenon M...

Colin Smith
  • Colin Smith

TheraCryf (TCF) | £4.3m raise to advance Ox-1 to clinical trial readin...

Further to the Chronos acquisition in 2024, TheraCryf has conditionally raised £4.25m to advance its Orexin programme to clinical trial readiness and now has a cash runway through the end of calendar 2026. The company expects to issue 1.7bn shares at 0.25p/share. While the discount is steep, TheraCryf believes it has the most selective Ox-1 inhibitor molecule in drug development with significant patent protection, targeting a market with multi-billion dollar potential for the treatment of addict...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch